RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia

DNA sequencing-based measurable residual disease (MRD) detection has shown to be clinically relevant in AML. However, the same methodology cannot be applied to fusion gene-driven subtypes of AML such as core-binding factor AML (CBF-AML). Here in this study, we evaluated the effectiveness of using DN...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, TaeHyung, Moon, Joon Ho, Ahn, Jae-Sook, Ahn, Seo-Yeon, Jung, Sung-Hoon, Yang, Deok-Hwan, Lee, Je-Jung, Shin, Myung-Geun, Choi, Seung Hyun, Lee, Ja-yeon, Tyndel, Marc S., Lee, Hui Young, Kim, Kyoung Ha, Cai, Yu, Lee, Yoo Jin, Sohn, Sang Kyun, Min, Yoo Hong, Cheong, June-Won, Kim, Hyeoung-Joon, Zhang, Zhaolei, Kim, Dennis Dong Hwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7674449/
https://www.ncbi.nlm.nih.gov/pubmed/33208771
http://dx.doi.org/10.1038/s41598-020-76933-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7674449/
https://www.ncbi.nlm.nih.gov/pubmed/33208771
http://dx.doi.org/10.1038/s41598-020-76933-2

Ejemplares similares